CDK4/6 inhibitors in Breast Cancer Therapy

CDK4/6 inhibitors in Breast Cancer Therapy

examines the pivotal role of CDK4/6 inhibition in treating hormone receptor-positive (HR+)/HER2-negative advanced breast cancer.

The book highlights FDA-approved applications of these inhibitors alongside endocrine therapy and explores ongoing research into their potential as neoadjuvant treatments.

It provides insights into the drug discovery and development of CDK4/6 inhibitors, covering their molecular mechanisms, pharmacology, and clinical applications.

The content addresses their use in mono and adjuvant therapies, as well as challenges in targeting, while also discussing market potential and post-marketing safety issues.

This book is a valuable resource for researchers and academics, enhancing understanding of CDK4/6 inhibitors' chemistry and therapeutic implications.

By presenting detailed information on clinical trials and market formulations, it equips the audience with essential knowledge to navigate the complexities of targeted breast cancer therapies and contributes to advancing research in this critical area.